The Washington Post reports agency scientists did not back the effort to ease access to unproven peptide drugs, a twist in the compounding policy fight.
Recap by typeshit. Full story at The Washington Post.
CNBC's investing team lifts its target on Lilly shares and argues the obesity drug run still has room to grow.
The Pharma Letter looks at how semaglutide generics are changing strategy in India, with Torrent eyeing an expansion into Brazil.
Semafor looks at how little national political figures have said about what the new class of weight loss drugs means for policy.
The doctors take on two of the topics their followers ask about most, giving their verdict on statins and Ozempic.
Up to 52% of patients on retatrutide went from severe apnea to mild or none over 80 weeks, against 13% on placebo, researchers report. The drug isn't approved yet.
STAT notes RFK Jr. and the MAHA movement have embraced peptides, though evidence for many of these wellness compounds is thin. A July FDA panel backed all six.
Loading…